<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43513">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539849</url>
  </required_header>
  <id_info>
    <org_study_id>ADA-FOS</org_study_id>
    <nct_id>NCT02539849</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease</brief_title>
  <official_title>Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that FOS increases counts of Faecalibacterium prausnitzii in faecal samples
      from Crohn's disease patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FOS increases counts of Faecalibacterium prausnitzii in faecal samples from Crohn's disease patients</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>adalimumab + FOS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FOS</intervention_name>
    <arm_group_label>adalimumab + FOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>adalimumab + FOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 65 years old

          -  Crohn's disease patients

          -  Inflammatory activity confirmed by imaging techniques (colonoscopy or magnetic
             resonance imaging (MRI))

          -  Refractory inflammatory luminal disease (with or without perianal involvement) at any
             level of the gastrointestinal tract requiring therapy with adalimumab,according to
             standard clinical practice.

          -  Stable maintenance of any other medication (corticosteroids and / or
             immunosuppressants and/or 5-aminosalicylic acid (5-ASA)) for the past 4 weeks

          -  Screening tests required for a safe administration of anti tumour necrosis factor
             (anti-TNF) antibodies will be performed according to standard clinical practice

        Exclusion Criteria:

          -  Subjects consuming prebiotic supplements (inulin, FOS, galactooligosaccharides (GOS))
             in their regular diet.

          -  Antibiotic use within the past 2 months

          -  Previous anti-TNF therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Borruel, MD</last_name>
      <phone>34 932746222</phone>
      <email>nborruel@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Aldeguer, MD</last_name>
      <phone>34 972 94 02 87</phone>
      <email>doctoraldeguer@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>August 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
